3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Active not recruiting
2
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
6
Thoracic
3
Sarcoma
3
Head & Neck
3
Genitourinary
3
Dermatologic
2
CNS
2
Breast
2
Other solid neoplasm
1
Gynecologic
1
Conditions
Stomach Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pelvic Neoplasms
1
Ovarian Neoplasms
1
Mesothelioma, Malignant
1
Liposarcoma
1
Fallopian Tube Neoplasms
1
Desmoplastic Small Round Cell Tumor
1
Colonic Neoplasms
1
Interventions
pembrolizumab
26
Cisplatin
15
Pemetrexed
14
Paclitaxel
14
Carboplatin
14
Nivolumab
9
Cyclophosphamide
9
Docetaxel
8
Injections
7
atezolizumab
6
Melphalan
6
olaparib
5
Gemcitabine
5
Filgrastim
5
tislelizumab
4
durvalumab
4
aldesleukin
4
Leucovorin
4
Irinotecan
4
Granulocyte Colony-Stimulating Factor
4
Etoposide
4
Bevacizumab
4
tocilizumab
3
spartalizumab
3
liposomal doxorubicin
3
ixabepilone
3
fludarabine
3
epacadostat
3
defactinib
3
adavosertib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
X-Rays
×
Other solid neoplasm
×
Clear all
NCT04213794
2025-02-20
TOASTIT
Mayo Clinic
Phase EARLY_PHASE1
Terminated
2 enrolled